bit.bio secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour sites.
26.07.2023
Two new disease models for Duchenne muscular dystrophy
bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...
bit.bio is industrialising human cell manufacturing
Industrialising human cell manufacturing will unleash the potential of synthetic biology for reproducible research and affordable ...
bit.bio launches new custom disease model cells offering, advancing disease research & drug discovery
Offering will provide robust, standardised tools for research and drug discovery.
Weslie Janeway - investor, scientist, philanthropist joins bit.bio Board
Weslie Janeway - investor, philanthropist, and scientist - joins bit.bio's Board of Directors.
Collaborating with Mekonos to advance non-viral cell engineering
This collaboration will combine the Mekonos novel ex vivo delivery platform with bit.bio’s opti-ox precision cellular reprogrammin...
Silicon Valley Bank statement
Statement from our CFO on the situation concerning SVB.
bit.bio partners with Automata on key aspect of human cell production
bit.bio will use Automata to automate a key aspect of its production of iPSC derived human cells
bit.bio expands independent Ethics and Sustainability Board
New advisors will provide important and independent guidance.